Transcatheter mitral valve repair (TMVr) with the MitraClip device is an increasingly important part of the clinical armamentarium for treatment of mitral regurgitation (MR). TMVr provides significant quality of life and prognostic benefits in.
In an elderly high-risk population with aortic stenosis, our TAVI program reports a 30-day and 17-month mortality of 3% and 8%, respectively. These clinical outcomes are remarkable when compared with international benchmarks.